Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1956 1
1958 1
1961 3
1962 1
1963 2
1964 2
1965 1
1966 3
1969 3
1970 4
1971 5
1974 1
1976 2
1977 3
1978 1
1979 1
1980 4
1981 6
1982 1
1983 2
1984 1
1985 3
1986 1
1987 3
1988 1
1989 3
1990 4
1991 2
1992 7
1993 5
1994 12
1995 6
1996 4
1997 8
1998 15
1999 11
2000 15
2001 12
2002 7
2003 5
2004 11
2005 5
2006 11
2007 11
2008 9
2009 12
2010 15
2011 22
2012 29
2013 32
2014 44
2015 21
2016 14
2017 22
2018 24
2019 19
2020 38
2021 31
2022 31
2023 35
2024 38
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

599 results

Results by year

Filters applied: . Clear all
Page 1
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, Okumura N, Yamaguchi M, Ikeda N, Wakabayashi M, Nakamura K, Fukuda H, Nakamura S, Mitsudomi T, Watanabe SI, Asamura H; West Japan Oncology Group and Japan Clinical Oncology Group. Saji H, et al. Among authors: wakabayashi m. Lancet. 2022 Apr 23;399(10335):1607-1617. doi: 10.1016/S0140-6736(21)02333-3. Lancet. 2022. PMID: 35461558 Clinical Trial.
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.
Aokage K, Suzuki K, Saji H, Wakabayashi M, Kataoka T, Sekino Y, Fukuda H, Endo M, Hattori A, Mimae T, Miyoshi T, Isaka M, Yoshioka H, Nakajima R, Nakagawa K, Okami J, Ito H, Kuroda H, Tsuboi M, Okumura N, Takahama M, Ohde Y, Aoki T, Tsutani Y, Okada M, Watanabe SI; Japan Clinical Oncology Group. Aokage K, et al. Among authors: wakabayashi m. Lancet Respir Med. 2023 Jun;11(6):540-549. doi: 10.1016/S2213-2600(23)00041-3. Epub 2023 Mar 6. Lancet Respir Med. 2023. PMID: 36893780 Clinical Trial.
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial.
Hattori A, Suzuki K, Takamochi K, Wakabayashi M, Sekino Y, Tsutani Y, Nakajima R, Aokage K, Saji H, Tsuboi M, Okada M, Asamura H, Nakamura K, Fukuda H, Watanabe SI; Japan Clinical Oncology Group; West Japan Oncology Group. Hattori A, et al. Among authors: wakabayashi m. Lancet Respir Med. 2024 Feb;12(2):105-116. doi: 10.1016/S2213-2600(23)00382-X. Epub 2024 Jan 3. Lancet Respir Med. 2024. PMID: 38184010 Clinical Trial.
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K. Fukuoka S, et al. Among authors: wakabayashi m. J Clin Oncol. 2020 Jun 20;38(18):2053-2061. doi: 10.1200/JCO.19.03296. Epub 2020 Apr 28. J Clin Oncol. 2020. PMID: 32343640 Clinical Trial.
A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer.
Suzuki K, Watanabe SI, Wakabayashi M, Saji H, Aokage K, Moriya Y, Yoshino I, Tsuboi M, Nakamura S, Nakamura K, Mitsudomi T, Asamura H; West Japan Oncology Group and Japan Clinical Oncology Group. Suzuki K, et al. Among authors: wakabayashi m. J Thorac Cardiovasc Surg. 2022 Jan;163(1):289-301.e2. doi: 10.1016/j.jtcvs.2020.09.146. Epub 2020 Nov 12. J Thorac Cardiovasc Surg. 2022. PMID: 33487427 Free article.
Lymph node dissection in small peripheral lung cancer: Supplemental analysis of JCOG0802/WJOG4607L.
Maniwa T, Okami J, Miyoshi T, Wakabayashi M, Yoshioka H, Mimae T, Endo M, Hattori A, Nakagawa K, Isaka T, Isaka M, Kita R, Sekino Y, Mitome N, Aokage K, Saji H, Nakajima R, Okada M, Tsuboi M, Asamura H, Fukuda H, Watanabe SI; West Japan Oncology Group and Japan Clinical Oncology Group. Maniwa T, et al. Among authors: wakabayashi m. J Thorac Cardiovasc Surg. 2024 Sep;168(3):674-683.e1. doi: 10.1016/j.jtcvs.2023.11.023. Epub 2023 Nov 23. J Thorac Cardiovasc Surg. 2024. PMID: 38000629
Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, Yoshino T. Bando H, et al. Among authors: wakabayashi m. Clin Cancer Res. 2022 Mar 15;28(6):1136-1146. doi: 10.1158/1078-0432.CCR-21-3213. Clin Cancer Res. 2022. PMID: 35063964 Free PMC article.
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, Ueyama H, Fujisaki T, Saigusa Y, Yamaji T, Azushima K, Urate S, Suzuki T, Abe E, Wakui H, Tamura K. Yamada T, et al. Among authors: wakabayashi m. Cardiovasc Diabetol. 2021 Jan 7;20(1):14. doi: 10.1186/s12933-020-01197-z. Cardiovasc Diabetol. 2021. PMID: 33413348 Free PMC article.
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.
Takei S, Tanaka Y, Lin YT, Koyama S, Fukuoka S, Hara H, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishima S, Ueno T, Kojima S, Wakabayashi M, Sakamoto N, Kojima M, Kuwata T, Yoshino T, Nishikawa H, Mano H, Endo I, Shitara K, Kawazoe A. Takei S, et al. Among authors: wakabayashi m. J Immunother Cancer. 2024 Feb 8;12(2):e008210. doi: 10.1136/jitc-2023-008210. J Immunother Cancer. 2024. PMID: 38336371 Free PMC article.
New classification Rome IV functional dyspepsia and subtypes.
Futagami S, Yamawaki H, Agawa S, Higuchi K, Ikeda G, Noda H, Kirita K, Akimoto T, Wakabayashi M, Sakasegawa N, Kodaka Y, Ueki N, Kawagoe T, Iwakiri K. Futagami S, et al. Among authors: wakabayashi m. Transl Gastroenterol Hepatol. 2018 Sep 19;3:70. doi: 10.21037/tgh.2018.09.12. eCollection 2018. Transl Gastroenterol Hepatol. 2018. PMID: 30363705 Free PMC article. No abstract available.
599 results